Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
$63.84
$0.33(1.68%)
At close: 4:00 PM EST
$63.84
$0.33(1.68%)
Day’s Range― - ―
52-Week Range$9.57 - $76.76
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.79M
Market Cap
$9.00B
Enterprise Value$2.78B
Total Cash (Recent Filing)$900.37M
Total Debt (Recent Filing)$713.29M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Feb 10, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding135,879,650
10 Day Avg. Volume3,545,767
30 Day Avg. Volume2,785,794
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue4.66
Enterprise Value/Gross Profit4.82
Enterprise Value/Ebitda-52.95
Forecast
1Y Price Target
$76.50Price Target Upside19.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.3
Revenue Forecast (FY)$390.02M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEarly-stage data showing rapid reductions in visceral fat while preserving lean muscle suggest the INHBE program could offer a differentiated obesity treatment profile with meaningful body-composition benefits.
Combination Therapy StrategyEvidence that combining the INHBE candidate with GLP-1 therapy produced substantially larger weight and fat reductions implies a complementary role in combination regimens, which could expand clinical use alongside existing incretin drugs.
Regulatory Approval And Commercial PositioningFDA approval of Redemplo with a clean label and a single-pricing approach reduces commercial uncertainty and, together with milestone payments from partners, provides initial revenue and development funding support.
Bears Say
Capital And Dilution RiskAnalyst models that assume future equity raises highlight the risk of shareholder dilution and signal potential funding challenges for advancing multiple clinical programs.
Market CompetitionStronger-than-anticipated uptake of a competing triglyceride therapy may constrain market share for Arrowhead's related products and slow commercial adoption in overlapping indications.
Valuation And Investor ExpectationsHigh investor expectations and an analyst Market-Perform stance indicate valuation risk, where optimism for early-stage data may already be reflected in the share price and limit upside from incremental preclinical updates.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $76.76 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $9.00B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Feb 10, 2026 which is in 23 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Nov 25, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.112 by $0.002.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is 0.11.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 135,879,650 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.112. Following the earnings report the stock price went up 23.338%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$76.50 (19.83% Upside)
$76.50 (19.83% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
249.97%
12-Months-Change
Fundamentals
Return on Equity
-0.50%
Trailing 12-Months
Asset Growth
27.25%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
ARWR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant highlights including the FDA approval of Rodemplo, robust financial performance, and substantial milestone payments indicating a successful transition to a commercial stage. However, there are some challenges in program timelines and regulatory claims that need to be addressed.View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
$76.50
▲(19.83% Upside)
Technical Analysis
Ownership Overview
3.81% Insiders
18.39% Mutual Funds
0.53% Other Institutional Investors
49.55% Public Companies and
Individual Investors